Precision and accuracy in the quantitative analysis of biological samples by accelerator mass spectrometry: Application in microdose absolute bioavailability studies

Analytical Chemistry

Volumn 83, Issue 14, 2011, Pages 5607-5616

  Gao, Lan ^a   Li, Jing ^a   Kasserra, Claudia ^a   Song, Qi ^b   Arjomand, Ali ^b   Hesk, David ^a   Chowdhury, Swapan K ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Accium BioSciences Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCELERATOR MASS SPECTROMETRY; AREA UNDER THE CURVES; BIOANALYTICAL; BIOANALYTICAL METHODS; BIOAVAILABILITY STUDY; BIOLOGICAL SAMPLES; CALIBRATION STANDARD; CENTER FOR VETERINARY MEDICINES; CONCENTRATION DETERMINATION; CORRELATION COEFFICIENT; DEPARTMENT OF HEALTHS; DRUG EVALUATION; FOOD AND DRUG ADMINISTRATION; HUMAN PLASMA SAMPLES; HUMAN SERVICES; ISOTOPIC RATIOS; LC-MS/MS; LINEAR RESPONSE RANGE; LOW CONCENTRATIONS; LOWER LIMIT OF QUANTITATIONS; MICRODOSE; ORAL ADMINISTRATION; ORAL DOSE; PLASMA CONCENTRATION; REGRESSION FUNCTION; SAMPLE ANALYSIS; SAMPLING TIME; STANDARD DEVIATION;

BIOCHEMISTRY; CALIBRATION; MASS SPECTROMETRY; PARTICLE ACCELERATORS; PLASMAS; STANDARDS; VETERINARY MEDICINE;

QUALITY CONTROL;

ANTIVIRUS AGENT; DIPEPTIDE; NARLAPREVIR; SULFONE;

ADULT; ARTICLE; BLOOD; CALIBRATION; EVALUATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIQUID CHROMATOGRAPHY; MALE; METHODOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; CALIBRATION; CHROMATOGRAPHY, LIQUID; DIPEPTIDES; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SULFONES; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 79960377816     PISSN: 00032700     EISSN: None     Source Type: Journal    
DOI: 10.1021/ac2006284     Document Type: Article

References (47)

1. Brown, T. R. Clin. Pharmacokinet. 1990, 18, 423-433
2. Ma, S.; Chowdhury, S. K.; Alton, K. B. Curr. Drug Metab. 2006, 7, 503-523
3. Ramanathan, R.; Reyderman, L.; Kulmatycki, K.; Su, A.-D.; Alvarez, N.; Chowdhury, S. K.; Alton, K. B.; Wirth, M. A.; Clement, R. P.; Statkevich, P.; Patrick, J. E. Xenobiotica 2007, 37, 753-769
4. Ramanathan, R.; Reyderman, L.; Su, A.-D.; Alvarez, N.; Chowdhury, S. K.; Alton, K. B.; Wirth, M. A.; Clement, R. P.; Statkevich, P.; Patrick, J. E. Xenobiotica 2007, 37, 770-787
5. Muller, R. A. Science 1977, 196, 489-494
6. Turteltaub, K. W.; Dingley, K. H.; Curtis, K. D.; Malfatti, M. A.; Turesky, R. J.; Garner, R. C.; Felton, J. S.; Lang, N. P. Cancer Lett. (Shannon, Irel.) 1999, 143, 149-155
7. Litherland, A. E. Annu. Rev. Nucl. Part. Sci. 1980, 30, 437-473
8. Elmore, D.; Phillips, F. M. Science 1987, 236, 543-550
9. Turteltaub, K. W.; Mauthe, R. J.; Dingley, K. H.; Vogel, J. S.; Frantz, C. E.; Garner, R. C.; Shen, N. Mutat. Res. 1997, 376, 243-252
10. Weaver, C. M. Bone 1998, 22, 103S-104S
11. Hohl, C.; Gerisch, P.; Korschinek, G.; Nolte, E.; Ittel, T. H. Nucl. Instrum. Methods Phys. Res., Sect. B 1994, 92, 478-482
12. Yokel, R. A.; Florence, R. L. Toxicology 2006, 227, 86-93
13. Clifford, A. J.; Arjomand, A.; Dueker, S.; Schneider, P.; Buchholz, B.; Vogel, J. S. Adv. Exp. Med. Biol. 1998, 445, 239-251
14. Wilding, I. R.; Bell, J. A. Drug Discovery Today 2005, 10, 890-894
15. Lappin, G.; Garner, R. C. Anal. Bioanal. Chem. 2004, 378, 356-364
16. Barker, J.; Garner, R. C. Rapid Commun. Mass Spectrom. 1999, 13, 285-293
17. Turteltaub, K. W.; Vogel, J. S. Curr. Pharm. Des. 2000, 6, 991-1007
18. Garner, R. C. Curr. Drug Metab. 2000, 1, 205-213
19. Lappin, G.; Garner, R. C. Nat. Rev. Drug Discovery 2003, 2, 233-240
20. Lappin, G.; Garner, R. C. Expert Opin. Drug Metab. Toxicol. 2005, 1, 23-31
21. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry, Investigators, Reviewers: Exploratory IND Studies (ucm078933), Januray 2006. http://www.fda.gov/downloads/Drugs/ GuidanceCompilanceRegulatoryInformation/Guidances/ucm078933.pdf. Accessed March 1, 2011.
22. European Medicines Agency. Position Paper on Non-Clinical Safety Studies to Support Clinical Trials with a Single Microdose (CPMP/SWP/2599/02/rev 1), June 23, 2004. http://www.tga.gov.au/pdf/euguide/swp259902r1en.pdf. Accessed March 1, 2011.
23. Garner, R. C.; Lappin, G. Br. J. Clin. Pharmacol. 2006, 61, 367-370
24. Lappin, G.; Rowland, M.; Garner, R. C. Expert Opin. Drug Metab. Toxicol. 2006, 2, 419-427
25. Sarapa, N.; Hsyu, P.-H.; Lappin, G.; Garner, R. C. J. Clin. Pharmacol. 2005, 45, 1198-1205
26. Azzaro, A. J.; Ziemniak, J.; Kemper, E.; Campbell, B. J.; VanDenBerg, C. J. Clin. Pharmacol. 2007, 47, 1256-1267
27. Wade, M.; Baker, F. J.; Roscigno, R.; DellaMaestra, W.; Hunt, T. L.; Lai, A. A. J. Clin. Pharmacol. 2004, 44, 83-88
28. Klem, B.; Lappin, G.; Nicholson, S.; van de Wetering, J.; de Vries, D. E.; Oosterhuis, B.; Garner, R. C. J. Clin. Pharmacol. 2006, 46, 456-460
29. Smith, P. F.; Forrest, A.; Ballow, C. H.; Martin, D. E.; Proulx, L. Antimicrob. Agents Chemother. 2000, 44, 1609-1615
30. Vogel, J. S.; Lover, A. H. Methods Enzymol. 2005, 402, 402-422
31. Salehpour, M.; Possnert, G.; Bryhni, H. Anal. Chem. 2008, 80, 3515-3521
32. Lappin, G.; Simpson, M.; Shishikura, Y.; Garner, C. Anal. Biochem. 2008, 378, 93-95
33. Zoppi, U.; Crye, J.; Song, Q.; Arjomand, A. Radiocarbon 2007, 49, 171-180
34. Garner, R. C.; Barker, J.; Flavell, C.; Garner, J. V.; Whattam, M.; Young, G. C.; Cussans, N.; Jezequel, S.; Leong, D. J. Pharm. Biomed. Anal. 2000, 24, 197-209
35. Keck, B. D.; Ognibence, T. J.; Vogel, J. S. Bioanalysis 2010, 2, 469-485
36. Dueker, S. R.; Vuong, L. T.; Lohstron, P. N.; Giacomo, J. A.; Vogel, J. S. Adv. Drug Delivery Rev. 2011, 63, 518-531
37. Young, G.; Ellis, W.; Ayrton, J.; Hussey, E.; Adamkiewicz, B. Xenobiotica 2001, 31, 619-632
38. Zhang, J.-H.; Chung, T. D.; Oldenburg, K. R. J. Biomol. Screening 1999, 4, 67-73
39. Sui, Y.; Wu, Z. J. Biomol. Screening 2007, 12, 229-234
40. Ognibene, T. J.; Bench, G.; Vogel, J. S.; Peaslee, G. F.; Murov, S. Anal. Chem. 2003, 75, 2192-2196
41. Gao, L.; Chowdhury, S. K. In Using Mass Spectrometry for Drug Metabolism Studies, 2 nd ed.; Korfmacher, W., Ed.; CRC Press: New York, 2009; pp 391-418.
42. Brown, K.; Tompkins, E. M.; White, I. N. H. Mass Spectrom. Rev. 2006, 25, 127-145
43. Hellborg, R.; Skog, G. Mass Spectrom. Rev. 2008, 27, 398-427
44. See the Supporting Information.
45. Miyashita, M.; Presley, J. M.; Buchholz, B. A.; Lam, K. S.; Lee, Y. M.; Vogel, J. S.; Hammock, B. D. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 4403-4408
46. Lappin, G.; Seymour, M.; Young, G.; Higton, D.; Hill, H. M. Bioanalysis 2011, 3, 407-410
47. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). Guidance for Industry: Bioanalytical Method Validation (ucm070107), May 2001. http://www.fda.gov/downloads/Drugs/ GuidanceCompilanceRegulatoryInformation/Guidances/ucm070107.pdf. Accessed March 1, 2011.